分类： aa

At the China International Fair for Trade in Services in 2020, the domestic COVID-19 vaccine made its first stunning appearance as the "main coffee", which was widely concerned by public opinion. With the increasing popularity of vaccines in COVID-19, the discussion about vaccines in COVID-19 has led to rumors such as "high-priced vaccines", "ineffective vaccines" and "unsafe vaccines". In this regard, I really smashed the false rumors and decrypted the COVID-19 vaccine on the China Internet joint rumor platform. Let’s take a look.

1. After Covid-19 mutates, the vaccine will be invalid?

Because Covid-19 infected people can still be reinfected after recovery, there are rumors that Covid-19 mutates too fast, so it is difficult for the vaccine to cover the mutated Covid-19, and it will not be effective.

On September 7th, 2020, COVID-19 inactivated vaccine was presented at the Trade Fair. (Source: vision china)

Chen Wei, a national honorary title winner of "People’s Hero", an academician of China Academy of Engineering and a researcher at the Institute of Military Medicine of Academy of Military Sciences, responded that up to now, the recombinant COVID-19 vaccine developed in China can completely cover the mutated Covid-19.

In addition, according to the data, several subtypes are indeed mutating in Covid-19 at present, but its main gene sequence and protein level have not changed fundamentally, so it is no problem for COVID-19 inactivated vaccine to deal with these mutated viruses in the next few years.

Really: the virus mutation is not terrible, and the vaccine works.

Second, the price of vaccines in COVID-19 is too high for ordinary people to afford?

On September 5th, the staff displayed the specific immunoglobulin at the biological booth of Sinopharm Group China in the public health and epidemic prevention area of the International Trade Fair. Xinhua News Agency reporter Zhang Yuwei photo

Regarding the pricing of vaccines in COVID-19, Zheng Zhongwei, director of the Science and Technology Development Center of the National Health and Wellness Commission and head of the vaccine research and development special class working group of the the State Council Joint Prevention and Control Mechanism, said that COVID-19 vaccines belong to public health products, and their pricing will not be based on the contradiction between supply and demand in the market, but on the cost.

Yin Weidong, chairman, president and CEO of Kexing Bio, also said that the price of vaccine will fluctuate due to different purchasers and different purchasing scales, but the final price will be at the level of 100 yuan, which will not exceed 1,000 yuan.

Zhenzhen: COVID-19 vaccine will be on the market, and vaccination and epidemic prevention can be expected.

Three, COVID-19 vaccine will have side effects, unsafe?

Not long ago, a false news that "Putin’s daughter died because of the side effects of injecting COVID-19 vaccine" spread wildly on the Internet, which shows that the safety and side effects of COVID-19 vaccine have always been the focus of attention.

Comics: Vaccine and Coronavirus (Source: vision china)

In response to public doubts and concerns, Academician Chen Wei pointed out that the results of the first phase clinical trial of recombinant COVID-19 vaccine showed that all 108 people vaccinated produced antibodies. Phase I and phase II clinical trials have proved the effectiveness and safety of the vaccine, and phase III clinical trials will evaluate the effectiveness and safety of the vaccine on a larger scale.

It is worth noting that China officially started the emergency use of COVID-19 vaccine on July 22nd, and Beijing is the first city to start the emergency use of vaccine. At present, there is no obvious adverse reaction and no one infected with the vaccine.

Zhenzhen: The vaccine is safe and secure. Don’t let rumors disturb the prevention and control.

4. Will vaccination affect the results of nucleic acid testing?

Some netizens are worried that vaccination will have an impact on nucleic acid detection. In this regard, Zhou Song, General Counsel of China Biology of Sinopharm Group, made it clear that it would not, because the nucleic acid test detects antigens, and people produce protective antibodies after being vaccinated with COVID-19 vaccine, so the nucleic acid test will not be affected.

Really: the antigen and antibody are clearly divided, so don’t worry about vaccination.

Ten Questions and Ten Answers about Zhenzhen Popular Science

1. What is the vaccination method? Intramuscular injection.

2. What is the vaccine type in COVID-19? Inactivated vaccine, nucleic acid vaccine, recombinant protein vaccine, adenovirus vector vaccine, attenuated influenza virus vector vaccine.

3. What is the vaccine protection period? About 1-3 years.

4. When will the vaccine be available? Inactivated vaccine will be available at the end of December at the earliest.

5. How long does it take to produce antibodies after vaccination? After 28 days of vaccination with two doses of vaccine according to the standard immunization program, high titer antibody enough to resist Covid-19 can be produced.

6. What is the vaccination frequency? According to the virus infection.

7. Which groups of people are given priority in vaccination? Employees in key sectors and high-risk groups, including the elderly and people with basic diseases.

8. Can women during lactation and pregnancy be vaccinated? It is recommended to suspend vaccination.

9. Does everyone need to be vaccinated? No.

10. What is the mass production of vaccine? In the future, the annual production capacity will reach 80 to 1 billion doses.

(Source: Xinhua News Agency, CCTV Finance, Voice of China, Central Radio and Television Station, etc.)

Source: China Internet Joint Rumor Platform

Original title: "What you should know about COVID-19 vaccine"

Read the original text

　　According to the "Botou CDC" news, recently, a cluster epidemic occurred in Haohui Trading Co., Ltd., Xiaoqiao Town, Jinzhou City. In order to effectively control and reduce the spread risk of COVID-19 epidemic and effectively protect people’s health and life safety, relevant matters are hereby notified as follows:

　　1. The residents who have purchased related products online from Jinzhou Haohui Trading Co., Ltd. since October 18th are requested to fully disinfect and sterilize the received packages, and seal the packages. Those who come into contact with the packages should take the initiative to report to their towns (streets, development zones) and work units, and cooperate with the screening, testing, control and other work. Anyone who fails to report truthfully, causing the spread risk of COVID-19 epidemic or other serious consequences, will be investigated for responsibility according to law.

　　Two, the city residents don’t have to leave the local, try to reduce the flow of people.

3. If you find that there are people around you who have not taken the initiative to report, please actively call the epidemic prevention and control office to report.

　　5G commercial "landing" will be over one year. Guangzhou Daily all-media reporter Yang Yaozhen photo

　　Guangjing observation

　　Text/Guangzhou Daily All-Media Reporter Wen Jing, Zhang Lu

　　Ms. He, a citizen, has recently received frequent calls from operators’ customer service to promote 5G packages. "The tariff package will cost more than 100 yuan, so I will not consider raising 5G for the time being." The reporter visited the market and learned that for the first anniversary of the official "landing", the "overwhelming" promotion of the market side is in stark contrast to the rational treatment of some consumers. "Sales say that only when you buy a 5G mobile phone and upgrade the package can you get the operator’s subsidy." Aunt Liang just bought a 500-yuan 5G mobile phone for her son in high school, but she said that if there is no subsidy of several hundred yuan, she will still choose a 4G mobile phone.

　　The survey found that the lack of choice of 5G packages, the high cost, the lack of low-end mobile phones and the lack of "killer" applications have become the embarrassment and helplessness for consumers to transition from 4G to 5G.

　　Fees:

　　The price of 5G package is relatively high.

　　"My monthly mobile phone package fee is 88 yuan/month, which includes 30G traffic. There is WiFi in my office and home, and the monthly traffic is inexhaustible. Sometimes I open hotspots to share with my family." Miss He, a citizen, received customer service calls from operators from time to time in recent months, but she said that she couldn’t figure out why she had to upgrade to 5G package.

　　Although operators have recently launched a variety of 5G packages, 5G packages are still "expensive" in comparison. For example, the mobile 5G package, the cheapest is 89 yuan/month; The lowest 5G package for telecom is 129 yuan/month; Unicom’s cheapest 5G package is also 129 yuan/month. In other words, now a new 5G package will cost at least 100~130 yuan per month.

　　According to the Survey Report on the Experience and Attitude of 5G Mobile Phone Users in China in 2020 released by a third party organization, the tariff of 5G mobile phone communication package is too high, and 49.2% of the interviewed 5G mobile phone users think that the current package price is too high, while 44.8% of the interviewed non-5G mobile phone users think that the high price of 5G communication package is the reason why they don’t buy 5G mobile phones.

　　Embarrassed:

　　Lack of phenomenal applications affects the popularity of 5 G.

　　According to the data of ICT Institute, in September, 26 new models of 5G mobile phones were listed in the domestic market, accounting for 44.8% of the number of new models listed in the same period, and the shipment volume was 13.99 million units, accounting for 60.0% of the mobile phone shipments in the same period, which has reached 60% for four consecutive months.

　　For the entire domestic smart phone market, the development of 5G mobile phones can be described as "outstanding". Domestic mainstream manufacturers Huawei, vivo, OPPO, Xiaomi, Glory, etc. have covered the 5G mobile phone market at different price points, and there are models to choose from from the high-end price of more than 5,000 yuan to the low-end price of 1,500 yuan.

　　"One of the main factors affecting the popularity of 5G is the lack of phenomenal applications," the reporter said in interviews with many insiders. Looking back at the transition from 3G to 4G, consumers really feel the need to change 4G mobile phones. WeChat "grabbing red packets" is one of them, as well as short videos, live broadcasts, mobile games, take-out and mobile payment.

　　In the face of the new 5G, industry insiders say that there are opportunities for phenomenal applications in private cloud, ultra-high-definition live broadcast, large-capacity video and the increasingly popular Vlog. In April this year, the three operators jointly released the White Paper on 5G Information. Will the 5G information created by operators "run out" in the next 5G era? According to the analysis, 5G information will become the first domestic and popular 5G application, which will create new market opportunities.

　　Expert:

　　Low-end terminals need to increase development efforts.

　　Compared with personal consumption, after a year of development, 5G presents another scene in the industry. According to the latest data, from January to August, 61,625 new 5G base stations were built in Guangdong. The number of 5G package users in the province reached 20.74 million, and a total of 98,613 5G base stations were built. Among them, Guangzhou 5G Industrial Park was approved as one of the first batch of 5G industrial parks in Guangdong Province.

　　According to industry experts, the important value of 5G network is to go out of the communication industry and apply it to thousands of industries, and the difficulty lies in how to combine it with the needs of the industry and provide power for the digitalization of the industry through innovative scene applications and operation modes.

　　Recently, Wu Hequan, an academician of China Academy of Engineering, mentioned in his keynote speech at the main forum of the IMT-2020(5G) conference that on the first anniversary of the commercialization of 5G, while seeing the achievements, we also need to face up to the existing problems such as immature technology, high operating cost and difficulty in digesting costs. The development of 5G is inseparable from innovation, and it also requires broader cooperation in the industrial chain. Wu Hequan pointed out that at present, there are not many varieties of mobile phones to choose from, and few of them are below 1,000 yuan. In the future, the demand for low-end terminals will be greater, and development efforts should be intensified. In the industry terminal, it is necessary to enrich industry modules and chips through cross-border cooperation with vertical industries, but the current cooperative business model is still unclear.

　　Reporter observation:

　　On November 1 last year, China’s 5G package was declared "landing". According to the latest data from the Ministry of Industry and Information Technology, China has opened a total of 690,000 5G base stations, with more than 160 million connected users. By the end of September, China has basically achieved 5G coverage in cities. According to the data disclosed by the basic operators, the combined number of 5G package users of China Mobile and China Telecom has reached 178 million.

　　In fact, after a year of popularization, the public’s awareness of 5G has improved, but most people are not willing to upgrade 5G, and it is generally believed that the current prices of 5G terminals and 5G packages are on the high side, so they choose to wait and see. Operators and terminal manufacturers should launch more low-priced versions of 5G tariff packages and more cost-effective 5G terminals, and increase application research and development in order to make consumers really willing to pay for 5G.

A few days ago, according to overseas media, Tesla’s modified Model Y model will be officially launched in early 2025, and it will take the lead in mass production and sales in China, and it is expected to be listed and sold in some overseas regions such as North America and Europe in the first half of the same year. The main competitors at the same level include Mustang Mach-E, Hyundai Ioniq 5, Volkswagen ID.4 and Nissan Ariya.

As can be seen from the previously released appearance renderings and spy photos, Tesla has changed the Model Y model, and the head is expected to be equipped with the same LED headlight group of the Model 3 model. For the first time, the rear part is equipped with a penetrating LED taillight group, which is more recognizable than the current models. It is understood that the new car will also launch a three-row six-seat version for consumers to choose from in China, and its body size is more advantageous than that in North America and Europe.

According to previous overseas media reports, Tesla’s modified Model Y model will upgrade the larger-capacity 95kWh battery pack, and simultaneously launch standard battery life, four-wheel drive standard battery life, four-wheel drive long battery life and Performanc high-performance four-wheel drive version for consumers to buy. In the interior part, the new car will also draw on the same design elements of the Model 3 model, equipped with a new multi-function steering wheel, and equipped with a large-size floating LCD central control screen and an 8-inch touch screen in the back row.

Recently, Tengshi D9 was officially released and opened for pre-sale. The new car launched four DM-i models and two EV models, of which the pre-sale price of DM-i version was 335,000-445,000, and that of EV version was 390,000-460,000. At the same time, the new car also launched 99 founding models with a price of 660,000 yuan.

Tengshi D9 is the first MPV of Tengshi brand. The new car adopts a brand-new π-Motion design language. The middle net is shaped like a π-shape, and the interior adopts two design styles: horizontal and straight waterfall. The horizontal grille is chrome-plated with lattice diamond carving, which shows a luxurious and exquisite visual impression. The waterfall grille is decorated with dense chrome-plated strips, which looks more luxurious.

Tengshi D9 has a length, width and height of 5250/1960/1920mm and a wheelbase of 3110mm, and its extremely advantageous body size brings spacious seating space for the car. The lateral lines are smooth and slender, and the wide silver chrome-plated ornament is added at the rear window, which enhances the luxury and exquisiteness of the whole vehicle. Equipped with UWB key, the 8-meter induction opening of the rear door can be realized, which improves the driving convenience. Equipped with multi-spoke aluminum alloy wheel shape, which matches the style of the whole vehicle.

The tail shape creates a concave-convex surface, the roof is added with a spoiler, and the interior of the penetrating taillight adopts an arrow-shaped layout, which is very recognizable. Silver chrome-plated parts are added to the tailgate and the rear enclosure, which further enriches the layering of the tail.

The interior adopts an embracing cockpit layout, equipped with a dual-spoke multi-function steering wheel, an all-LCD instrument panel, a 17.3-inch floating central control panel and a HUD head-up display function. It is equipped with Tengshi link system, which supports 5G, Bluetooth BT5.2 and WIFI6. Speech recognition supports continuous dialogue in the whole scene, supports 13 dialects and is powerful. The air outlet of air conditioner adopts rectangular strip design, which looks very avant-garde. It is also equipped with a crystal handle design, and a wireless charging board for mobile phones is also designed in front.

The new car has a 7-seat layout, with two independent seats in the second row, which supports the welcome function. The seats are designed with diamond texture, which is very classy. An independent operation screen is designed next to the armrest of the second row of seats, which can control the entertainment display and air conditioning.

In the power part, the new car uses DM-i hybrid power and pure electric power. DM-i uses Xiaoyun 1.5T engine and EHS electric hybrid system. The two-wheel drive version NEDC has a pure electric battery life of 190km and the longest battery life of 1040km, and the four-wheel drive version NEDC has a pure electric battery life of 180km and the longest battery life of 970km. The pure electric CLTC of the pure electric vehicle has a battery life of over 600km.

Editor’s comment:As a high-end MPV, Tengshi D90′ s competitors are not only joint venture brands such as Buick GL8 and Saina, but also independent high-end MPVs such as Lantu Dreamer, SAIC Chase MAXUS G90 and Roewe iMAX8 EV. Judging from the pre-sale price announced by Tengshi D90 at present, it is quite in line with expectations, and I look forward to the performance after listing.

Notice of the General Office of the National Health and Wellness Commission on Printing and Distributing the Basic Standards for Clinics in the Pilot Areas of Clinic Reform (Revised Edition in 2019)
Guo Wei Ban Yi Han [2019] No.802

Health and Wellness Committees of Beijing, Liaoning, Shanghai, Jiangsu, Zhejiang, Hubei, Guangdong, Sichuan and Shaanxi:

According to the requirements of "Opinions on Promoting the Development of Clinics" (Guo Wei Yi Fa [2019] No.39), our Committee organized and formulated the Basic Standards for Clinics in Pilot Areas of Clinic Reform (revised in 2019) (hereinafter referred to as the Basic Standards for Clinics in Pilot Areas, which can be downloaded from the website of the National Health and Wellness Commission). Is issued to you, please follow, and notify the relevant matters as follows:

First, the "Basic Standards for Clinics in Pilot Areas" is only used in 10 pilot cities of clinic reform, such as Beijing, Shanghai, Shenyang, Nanjing, Hangzhou, Wuhan, Guangzhou, Shenzhen, Chengdu and Xi ‘an, and will be promoted nationwide in due course according to the operating experience of the pilot cities.

Two, in the process of the implementation of the pilot reform of the clinic, the health administrative departments of the pilot cities shall, in accordance with the "Basic Standards for Clinics in Pilot Areas", review the clinics applying for filing, and issue the "Practice License for Medical Institutions" to meet the conditions.

Three, the health administrative departments of the pilot cities should strengthen the supervision and management of clinics, found that does not meet the "basic standards of clinics in pilot areas" to make rectification within a time limit, rectification is not implemented, the registration authority shall cancel the "practice license of medical institutions".

Attachment: Basic Standards for Clinics in Pilot Areas of Clinic Reform (revised in 2019)

General Office of National Health and Wellness Commission
October 30, 2019

(Information disclosure form: voluntary disclosure)

　　CCTV News:On September 14th, the Propaganda Department of the CPC Central Committee held a series of press conferences on the theme of "Ten Years in China". Jiang Wanrong, Vice Minister of Housing and Urban-Rural Development, introduced the high-quality development measures and achievements of housing and urban-rural construction in the new era and answered questions from reporters. Li Rusheng, chief engineer of the Ministry of Housing and Urban-Rural Development, said at the press conference that the pace of "going out" in the construction industry has also accelerated in the past decade. International competitiveness has been significantly enhanced, and foreign project contracting has spread to more than 190 countries and regions around the world. Since 2013, the turnover of foreign contracted projects and the amount of newly signed contracts have generally maintained a sustained growth trend. In 2021, 79 enterprises were selected into the list of the world’s largest 250 international contractors, and the number of enterprises and the proportion of business have been ranked first in the world since 2014. In the next step, we will further deepen the reform of the construction industry, adhere to the drive of innovation and the guidance of science and technology, promote the transformation, upgrading and high-quality development of the construction industry, continue to build the "Made in China" brand, and make greater contributions to the sustained and healthy development of the economy and society.

Source | Pharmacy (reproduced by Cybertron) Author | Medicine Circle Tao Ge At present, more than 10 multinational pharmaceutical companies have published 21-year financial reports. The author combed the revenue of multinational pharmaceutical companies in China market.　

According to the disclosure, the revenues of six multinational pharmaceutical companies in China are as follows:

Source of data: financial report, vertical and horizontal arrangement of pharmaceutical affairs (billion US dollars)

AstraZeneca’s total revenue in 2021 was USD 37.417 billion (including COVID-19 vaccine), up 41% (38% CER) year-on-year; Total revenue excluding vaccines increased by 26% (CER was 23%) to $33.436 billion, and R&D expenditure was $9.736 billion, an increase of 36%. In the fourth quarter of 2021, the total revenue increased by 62% (63% of CER) to $12.011 billion. AZ expects that the total revenue growth in FY22 will be around 15%, and the core earnings per share will increase by 20%. In 2021, AstraZeneca achieved revenue of US$ 6.011 billion, up 12% year-on-year. China District is one of the important sources of AstraZeneca’s revenue. Due to the pressure of price reduction caused by medical insurance negotiation and centralized purchase, AstraZeneca’s growth in China slowed down in 2021 H2, and Q4′ s revenue decreased by 4% year on year. It is predicted that in 2022, the performance of China District may decline in single digits, mainly due to the continuous influence of centralized purchasing and medical insurance. 　

Merck’s revenue in 2021 was US$ 48.704 billion, a year-on-year increase of 17%. Among them, the pharmaceutical business income was 42.754 billion US dollars, up 17% year-on-year; Animal health income was $5.568 billion, up 18% year-on-year. The revenue of K medicine was $17.2 billion, and the cervical cancer vaccine also contributed a lot to the revenue. In addition, the oral COVID-19 drug molnupiravir, which was urgently authorized for use in November last year, sold for 952 million US dollars in more than one month.

Merck China has also become the best performing region in the world in 2021, with a total revenue of US$ 4.262 billion, up 60% year-on-year.

Roche’s total revenue in 2021 was 62.801 billion Swiss francs (about 67.712 billion US dollars, according to the latest 1 Swiss franc = 10786 US dollars), up 9.3% year-on-year. Among them, the pharmaceutical business income was 45.041 billion Swiss francs, up 3.1% year-on-year, and the diagnostic business was 17.760 billion Swiss francs, up 29.5% year-on-year.

China’s pharmaceutical business income in 2021 was 3.276 billion Swiss francs (US$ 3.533 billion), accounting for 7.3% of Roche’s global pharmaceutical business income, up 4% year-on-year; Diagnostic business income was 2.43 billion Swiss francs, up 22% year-on-year.

Tumor sector: Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan (rituximab), Roche’s "third troika", continue to suffer from the strong impact of biological similar drugs, and their income in 2021 decreased by 38%, 37% and 28% respectively, totaling only 7.749 billion Swiss francs.

Tecentriq(+24%%), kadcyla(+16%) and Alecensa(+18) maintained good growth, which was difficult to offset the decline of established products, and the overall tumor business income still declined by 11%.

Sanofi’s net income in 2021 was 37.761 billion euros (US$ 43 billion), up by 7.1% year-on-year, including 26.970 billion euros (+7.6%) from pharmaceutical business, 6.323 billion euros (+6.8%) from vaccine business and 4.468 billion euros (+4.6%) from consumer health care business.

Sanofi’s pharmaceutical business mainly focuses on immune inflammation, nerves, rare diseases, tumors, and other fields. Dupixent is the core product of Sanofi at present. In 2021, the sales revenue increased by 52.7% year-on-year, and the sales reached 5.249 billion euros.

In June, 2020, it was approved to treat moderate and severe adult atopic dermatitis in China, and it was listed in the 2020 edition of the national medical insurance catalogue. In September, 2021, it was approved to expand the use of atopic dermatitis in adolescents over 12 years old in China.

In 2021, China’s revenue was 2.72 billion euros (US$ 3.098 billion), up by 7.9% year-on-year, mainly due to the growth of Dupixent and the recovery of Plavix from the influence of volume procurement.

Novartis’s net sales revenue in 2021 reached 51.626 billion US dollars, up 6% year-on-year. In 2021, the sales revenue of Novartis’ innovative drug sector was USD 42 billion, up by 8% year-on-year. At present, it is composed of Novartis Cancer and Novartis Pharmaceutical.

At present, the diseases covered by pharmaceutical business units mainly include immunization, blood diseases, skin diseases, ophthalmology, nerves, respiratory diseases, cardiovascular diseases, kidney and metabolic diseases and other mature diseases.

In terms of specific varieties, Cosentyx (Scochizumab) and Entresto (Shakubatrivasartan), a new drug for heart failure, contributed a total of $8.266 billion last year, which is the core drug driving Novartis’ performance growth.

In 2021, the sales revenue in China market was USD 3.052 billion, up by 18% year-on-year, accounting for 6% of Novartis’ total global revenue.

Lilly’s total revenue in 2021 was $28.318 billion, a year-on-year increase of 15%; Among them, China’s revenue was US$ 1.661 billion, up 49% year-on-year, and China’s market revenue in 2020 was US$ 1.117 billion.

Lilly’s current business mainly focuses on four major diseases: diabetes, tumor, immunity and nerve. The diabetes business has always been Lilly’s dominant and focused direction. Eight products, such as Trulicity (dulaglutide), Humulin (recombinant human insulin), Humalog (insulin lispro) and Jardiance (Engelje), generated revenue of $13.188 billion, accounting for 46.6% of the total revenue. Among them, the sales revenue of the fist product GLP-1 receptor agonist Trulicity reached 6.472 billion US dollars in 2021, and continued to maintain a steady and rapid growth of more than 20%.

References: financial reports of various companies; 1 Swiss franc = $1.0786; 1 Euro =1.1389 USD.

Golden car reward

On October 28th, 2025 long-life versions were listed in Hangzhou, among which the 222km long-life versions of Smart Horse and Lightning Horse were priced at 36,900 yuan and 39,900 yuan respectively.

In terms of product strength, the motor power of Xiaoma’s long battery life version reaches 30kW, which is 10kW more than the current model. In addition, the new car is equipped with APP remote car control function, which can open the air conditioner with one button and unlock the door. The fast charging function can increase the battery life by 100km after charging for one hour.

With the blessing of configuration, the starting price of Pentium Pony Long Life Edition is 36,900 yuan, which is more competitive than its competitors, Geely Panda and Hongguang MINIEV. However, the Pentium pony is still not confident enough. At the press conference, the Pentium pony has been emphasizing that it is a "FAW Pentium" model.

First of all, the self-confidence of Pentium Pony comes from the brand level. Compared with Geely Automobile and Automobile, which are independent head enterprises, and SAIC-GM-Wuling, which has been deeply involved in the field of micro-electric vehicles for a long time, the popularity and brand influence of Pentium brand are much smaller.

Secondly, in terms of vehicle-building strength, users are most worried about safety and quality for micro-electric vehicles. However, in order to achieve a higher safety factor, micro-electric vehicles also have high requirements for vehicle-building technology, and Pentium Pony is the first micro-electric vehicle of Pentium.

Therefore, with the endorsement of China FAW, a central enterprise, and the 70-year history of FAW Group, Pentium Automobile hopes to convince users of its own car-making strength and quality. Before the launch of the new car, Pentium also invited bloggers from online celebrity to visit and introduce the production technology of its Yancheng factory.

At the listing conference, Pentium also introduced the production and manufacturing of Yancheng factory at length. For example, Yancheng Factory adopts millions of UFC inspection tools, and the stamping parts are 100% inspected. The Pentium pony has gone through 1.26 million kilometers of road test, and the torsional stiffness of the car body has reached 14,370 m/.

Pentium brand has high hopes for Pentium pony because it bears the heavy responsibility of sales. According to the plan, the sales target of FAW Group’s own brands must reach 900,000 this year, and the sales of new energy vehicles must reach 500,000. This important task is mainly completed by Hongqi brand and Pentium brand.

From January to September, the cumulative sales volume of Pentium cars was 98,516 vehicles, up 19% year-on-year, among which the cumulative sales volume of new energy was 44,318 vehicles, up 113% year-on-year. At present, Pentium pony is the backbone of Pentium brand sales, with sales reaching 9615 vehicles in September, three times more than another new energy vehicle, Pentium NAT, and accounting for half of the total sales of Pentium brand.

But over-reliance on Pentium pony is not a good thing for Pentium brand. FAW Group has always had the goal of becoming a bigger and stronger independent brand. In May, 2021, at the brand-new strategy conference of the 15th anniversary of FAW Pentium, Pentium Automobile released a brand-new LOGO and brand positioning as "the middle and high-end brand in the mainstream automobile market in China".

Facing the "14th Five-Year Plan", FAW-Pentium set the ambition of achieving 300,000 vehicles in 2023, 600,000 vehicles in 2025 and challenging 1 million vehicles. However, in 2023, Pentium sold only 120,000 vehicles, and this year’s sales pressure is not small.

In terms of product planning, from 2023 to 2025, Pentium will complete the layout of five new energy products and eight traditional energy products at the speed of launching more than two new models every year, which will cover the mainstream passenger car market from A00 to B. However, the sales of Pentium T90 and Pentium NAT, which were launched in 2023, were not satisfactory.

For the current Pentium car, there is both sales pressure and the hidden worry of brand image decline. At present, other models of the Pentium brand are difficult to take on, but if the sales volume depends heavily on low-end micro-electric vehicles, it is not conducive to building a mid-to high-end brand positioning. According to the market demand, grinding out more explosion models with medium and high prices has become the direction that Pentium needs to focus on in the future.